Beyond Biotech - the podcast from Labiotech Labiotech's 15 biopharma companies to watch in 2026
32 snips
Jan 16, 2026 Roohi Peter, Labiotech reporter covering neuroscience and gene therapy. Willow Shah-Neville, Labiotech reporter tracking clinical-stage biotech and cardio/metabolic trials. Jules Adam, Labiotech reporter known for oncology and immunology analysis. They spotlight 15 biopharma companies to watch in 2026. Topics include gene and cell therapies, radiopharma and isotopes, microbiome commercialisation, GLP-1 rivalry, base editing, psychedelics trials, and novel neuroscience drugs.
AI Snips
Chapters
Transcript
Episode notes
Watch Cardigan's Multiple Late-Stage Readouts
- Cardigan's rapid fundraising enabled advancing three late-stage cardiovascular programs simultaneously; expect multiple 2026 data readouts.
- Track their phase results closely to assess whether their ambition to 'deliver multiple medicines quickly' is realistic.
Braveheart Bets On A Myosin Inhibitor From China
- Braveheart Bio acquired a tested cardiac myosin inhibitor from China and plans late-stage development in hypertrophic cardiomyopathy in 2026.
- Their candidate could compete with established myosin inhibitors and enter an active market soon.
Base Editing Promises Precision Without Cuts
- Beam Therapeutics' base editing makes single-base corrections without double-strand cuts, suggesting potentially higher precision and safety.
- Expect a broad clinical data update on BEAM-302 (AATD) in early 2026 and ongoing sickle-cell progress.